LifeMD Net Income From Continuing Ops from 2010 to 2025

LFMD Stock  USD 5.45  0.15  2.68%   
LifeMD's Net Loss is decreasing over the years with slightly volatile fluctuation. Net Loss is expected to dwindle to about -19.7 M. During the period from 2010 to 2025 LifeMD Net Loss annual values regression line had geometric mean of  4,580,712 and mean square error of 319.1 T. View All Fundamentals
 
Net Loss  
First Reported
2019-12-31
Previous Quarter
-5.5 M
Current Value
234.7 K
Quarterly Volatility
8.1 M
 
Covid
Check LifeMD financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LifeMD's main balance sheet or income statement drivers, such as Depreciation And Amortization of 10 M, Interest Expense of 2.3 M or Selling General Administrative of 76.3 M, as well as many indicators such as Price To Sales Ratio of 0.91, Dividend Yield of 0.0138 or Days Sales Outstanding of 14.8 M. LifeMD financial statements analysis is a perfect complement when working with LifeMD Valuation or Volatility modules.
  
Check out the analysis of LifeMD Correlation against competitors.

Latest LifeMD's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of LifeMD Inc over the last few years. It is LifeMD's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LifeMD's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

LifeMD Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(15,380,676)
Geometric Mean4,580,712
Coefficient Of Variation(141.60)
Mean Deviation17,396,352
Median(1,218,449)
Standard Deviation21,779,730
Sample Variance474.4T
Range60.1M
R-Value(0.61)
Mean Square Error319.1T
R-Squared0.37
Significance0.01
Slope(2,790,588)
Total Sum of Squares7115.3T

LifeMD Net Income From Continuing Ops History

2025-19.7 M
2024-18.7 M
2023-26.2 M
2022-45 M
2021-61.3 M
2020-60.5 M
2019-3.5 M

About LifeMD Financial Statements

LifeMD stakeholders use historical fundamental indicators, such as LifeMD's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although LifeMD investors may analyze each financial statement separately, they are all interrelated. For example, changes in LifeMD's assets and liabilities are reflected in the revenues and expenses on LifeMD's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in LifeMD Inc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-18.7 M-19.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether LifeMD Inc is a strong investment it is important to analyze LifeMD's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact LifeMD's future performance. For an informed investment choice regarding LifeMD Stock, refer to the following important reports:
Check out the analysis of LifeMD Correlation against competitors.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LifeMD. If investors know LifeMD will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LifeMD listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.53)
Revenue Per Share
5.157
Quarterly Revenue Growth
0.432
Return On Assets
(0.15)
Return On Equity
(24.63)
The market value of LifeMD Inc is measured differently than its book value, which is the value of LifeMD that is recorded on the company's balance sheet. Investors also form their own opinion of LifeMD's value that differs from its market value or its book value, called intrinsic value, which is LifeMD's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LifeMD's market value can be influenced by many factors that don't directly affect LifeMD's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LifeMD's value and its price as these two are different measures arrived at by different means. Investors typically determine if LifeMD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LifeMD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.